SynthesisJournal of neurology2026
Cerebral amyloid angiopathy-related inflammation (CAA-ri): an updated systematic review and meta-analysis.
Synthesis in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cerebral Amyloid Angiopathy-Related Inflammation Mimicking Leptomeningeal Metastasis After Resected Lung Adenocarcinoma: A Case Report Highlighting Dynamic Diagnostic Reassessment.Current oncology (Toronto, Ont.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCerebral amyloid angiopathy-related inflammation (CAA-ri) is a rare subtype of CAA, and it is correlated with pathological evidence of inflammation against amyloid-β in the walls of blood vessels and the surrounding tissue. Limited data exist on the prevalence of clinical, neuroimaging, and genetic characteristics in CAA-ri.
methodA systematic review and meta-analysis pooled data from published studies on CAA-ri. Random-effects models were used to calculate pooled prevalence rates, and heterogeneity was assessed using I
resultsWe identified 4 prospective and 22 retrospective cohort studies comprising 553 patients with CAA-ri (mean age, 70.9 years; women, 51.29%). Prevalence rates were: cognitive decline at presentation 66% ([95% CI 50-80%]; I
conclusionsCognitive decline and focal neurological deficits were the most common clinical features, while lobar cerebral microbleeds were the predominant neuroimaging finding. Forty-two percent of patients carried the homozygous APOE ε4/ε4 genotype, seventy-nine percent underwent steroid therapy, and favorable outcomes were observed in seventy-five percent of cases.
Indexed as
Identifiers
42387031What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.